Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


NAD refers Hollywood Health and Beauty to FTC

This article was originally published in The Tan Sheet

Executive Summary

The Council of Better Business Bureaus' National Advertising Division refers advertising for the weight-loss supplement Trimball-EXP200 to the Federal Trade Commission and FDA after marketer Hollywood Health and Beauty failed to respond to the industry self-regulation group's request for substantiation. NAD asked Hollywood Health and Beauty to support claims that Trimball-EXP200 "triggers automatic weight loss" and allows users to eat as much as they want and still lose weight. Testimonials that users lost "exactly 33 pounds without any effort" and "48 pounds in 7 weeks" also raised red flags. Under FTC's recently tightened guidelines for weight-loss testimonials, it is no longer sufficient to include a disclaimer that weight-loss results are not typical. Firms should disclose typical results, FTC says (1"The Tan Sheet" Oct. 12, 2009)

You may also be interested in...

National Advertising Division In Brief

Lunada's mice tests not "reliable predictor": Lunada Biomedical will discontinue claims for its Amberen menopausal relief supplement based on studies conducted with mice, according to the Electronic Retailing Self-Regulation Program. The division of the Council of Better Business Bureau said April 8 Lunada's evidence does not alleviate concerns about claims based on how the ingredient succinate affects mice. NAD questions whether the effect "is a reliable predictor of how the substance will perform on humans." The tests do not answer questions "particularly with respect to heart cells, liver tissue and reconstruction of bone mass," ERSP said. The industry watchdog group, which received an anonymous challenge, also recommended discontinuing or changing Amberen weight loss claims to clarify users' results were not clinically evaluated and expectations for the time needed for effects. ERSP agreed Los Angeles-based Lunada can promote its product's uniqueness, but should discontinue unqualified comparative superiority claims in the absence of head-to-head testing. ERSP agreed Lunada's claims regarding increased metabolism at the cellular level and normalization of the hypothalamus were not inappropriate based upon the evidence. The firm disagrees with ERSP's concerns and "strongly believes that it has well-founded arguments supporting" its claims, according to ERSP's case report. But Lunada, "out of deference to the forum and in the spirit of cooperation," said it will make future advertising consistent with the recommendations

FTC Testimonial Guide Moves Past "Results Not Typical," Enters Blog Era

The Federal Trade Commission raised the bar on substantiation and disclosure of "typical results" in testimonials and endorsements in advertising, in a revised guide released Oct. 5

EU Advances Plans For New Catalogs Of RWD Sources & Non-Interventional Studies

Users of the new catalogs will benefit from a modern technology with enhanced view, search, export and data submission functionalities, says the European Commission.


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts